Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2020-05-07 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
2019年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the 2019 Annual General Meeting (AGM) materials of 中源协和细胞基因工程股份有限公司, dated May 19, 2020. It contains detailed meeting agenda, including reports such as the 2019 Board of Directors Work Report, 2019 Supervisory Board Work Report, 2019 Annual Report, 2019 Financial Final Accounts Report, Profit Distribution Plan, and 2020 Financial Budget Report. It also includes proposals for board member nominations and other shareholder meeting matters. The document is comprehensive and lengthy (15,000 characters), containing substantive content typically presented at an AGM. It is not merely an announcement or a brief summary but the actual meeting materials and reports for the AGM. Therefore, it fits the category of AGM Information (AGM-R).
2020-05-07 Chinese
关于2019年年度股东大会增加临时提案的公告
AGM Information Classification · 95% confidence The document is an announcement related to the 2019 Annual General Meeting (AGM) of the company 中源协和细胞基因工程股份有限公司. It details the addition of a temporary proposal to the AGM agenda, the date and location of the meeting, voting procedures, and a list of proposals to be voted on, including board nominations and financial reports. The document does not contain the full annual report or financial statements but rather information about the AGM and its agenda items. The document length is 3613 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2020-05-07 Chinese
独立董事提名人声明（裴端卿）
Regulatory Filings
2020-04-28 Chinese
独立董事提名人声明（侯欣一）
Regulatory Filings
2020-04-28 Chinese
九届三十九次董事会会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 39th meeting of the 9th Board of Directors of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes approvals of various reports such as the 2019 Annual Report, financial reports, internal control reports, and proposals for the 2020 financial budget and financing plans. It also includes nominations for the 10th Board of Directors and independent directors, and other corporate governance matters. The document is not the actual annual report or financial statements but a formal announcement of board meeting decisions, including board member nominations and other management-related resolutions. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management and related board decisions. The document length (7038 characters) and content confirm it is not a brief notice or a report publication announcement but a substantive board meeting resolution announcement.
2020-04-28 Chinese
董事会审计委员会2019年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2019年度履职情况报告" (2019 Annual Performance Report) of the Board Audit Committee of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the activities, meetings, and evaluations conducted by the audit committee during 2019, including oversight of external auditors, internal audit guidance, and internal control assessments. It is a report on the audit committee's duties and performance rather than a standalone audit report or full annual report. The document length is 2285 characters, which is relatively short and focused on committee activities rather than full financial statements or audit opinions. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related committee reports, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence.
2020-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.